Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 3/20 | 0.53 |
| ▸ | DOHH | Q9BU89 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | COMT | P21964 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA9 | Q16790 | 3/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | KDM6A | O15550 | 1/20 | 0.35 |
| ▸ | KDM4A | O75164 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KDM5C | P41229 | 1/20 | 0.35 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.35 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10924548 | 0.84 | TYR (0.50) | TYRDOHHKDM4ECOMTCA12 | |
| SCHEMBL9453872 | 0.81 | TYR (0.50) | TYRDOHHKDM4ECOMTCA12 | |
| SCHEMBL16088174 | 0.80 | NPC1 (0.47) | TYRDOHHKDM4ECA12CA1 | |
| SCHEMBL10613124 | 0.79 | TYR (0.61) | TYRDOHHKDM4ECOMTCA12 | |
| SCHEMBL30982680 | 0.78 | NPC1 (0.49) | TYRDOHHKDM4E | |
| SCHEMBL30983057 | 0.78 | NPC1 (0.49) | TYRDOHHKDM4E | |
| SCHEMBL30982965 | 0.78 | NPC1 (0.49) | TYRDOHHKDM4E | |
| SCHEMBL9700040 | 0.76 | TYR (0.58) | TYRDOHHKDM4ECOMTCA12 | |
| SCHEMBL17128963 | 0.76 | DOHH (0.50) | TYRDOHHKDM4ECOMTCA12 | |
| SCHEMBL8102332 | 0.76 | DOHH (0.54) | TYRDOHHKDM4ECOMTCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0094149-A2 | Pharmaceutical compositions containing a complex of iron with N-substituted 3-hydroxypyrid-2-one or -4-one derivatives | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1983-11-16 | — | — | EP | claimed |
| EP-0093498-A2 | Pharmaceutical compositions containing N-substituted-3-hydroxypyrid-2-one or -4-one derivatives | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1983-11-09 | — | — | EP | claimed |
| WO-2023144379-A1 | HIGH-AFFINITY LIGANDS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED DELIVERY APPLICATIONS | PHILOCHEM AG (CH) | 2023-08-03 | — | — | WO | disclosed |
| EP-3891138-B1 | FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS | PHILOCHEM AG (CH) | 2022-01-12 | — | — | EP | disclosed |
| WO-2021160825-A1 | FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS | PHILOCHEM AG (CH) | 2021-08-19 | — | — | WO | disclosed |
| US-20160304485-A1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-10-20 | — | — | US | disclosed |
| US-6468688-B2 | CHARGING, DISCHARGING EFFICIENCY; VANADIUM ELECTROLYTE | PINNACLE VRB LIMITED (AU) | 2002-10-22 | — | — | US | disclosed |
| US-20010028977-A1 | Charging, discharging efficiency; vanadium electrolyte | JD HOLDING INC. (KY) | 2001-10-11 | — | — | US | disclosed |
| EP-0829104-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1998-03-18 | — | — | EP | disclosed |
| WO-1996035239-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-11-07 | — | — | WO | disclosed |
| US-5104865-A | IRON COMPLEXES OF HYDROXYPYRIDONES USEFUL FOR TREATING IRON OVERLOAD | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1992-04-14 | — | — | US | disclosed |
| EP-0138421-B1 | HYDROXYPYRIDONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1990-12-05 | — | — | EP | disclosed |
| US-4912118-A | Therapy for toxic concentration of metal | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1990-03-27 | — | — | US | disclosed |
| WO-1989009211-A1 | PROCESS FOR PRODUCING PYRID-4-ONES | THE ROYAL FREE HOSPITAL SCHOOL OF MEDICINE (GB) | 1989-10-05 | — | — | WO | disclosed |
| US-4840958-A | Novel 3-hydroxypyrid-2-ones and 3-hydroxyprid-4-ones useful in treating patients having a toxic concentration of iron | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1989-06-20 | — | — | US | disclosed |
| EP-0093498-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING N-SUBSTITUTED-3-HYDROXYPYRID-2-ONE OR -4-ONE DERIVATIVES | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1986-11-26 | — | — | EP | disclosed |
| US-4550101-A | Iron complexes of hydroxy pyridones useful for treating iron deficiency anemia | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1985-10-29 | — | — | US | disclosed |
| EP-0138421-A2 | Hydroxypyridone derivatives and pharmaceutical compositions containing them | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1985-04-24 | — | — | EP | disclosed |
| EP-0094149-A2 | Pharmaceutical compositions containing a complex of iron with N-substituted 3-hydroxypyrid-2-one or -4-one derivatives | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1983-11-16 | — | — | EP | disclosed |
| EP-0093498-A2 | Pharmaceutical compositions containing N-substituted-3-hydroxypyrid-2-one or -4-one derivatives | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1983-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304485-A1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | MCL1, BCL2L1, BCL2L11 | TYR 3967/4885DOHH 2691/4885KDM4E 1423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.